CA Agilent

Latest Content


Megane Aebischer, University of Geneva
1:38
Taking mRNA-LNP Analysis from R&D to QC
7 hours ago
by
Megane Aebischer
Routine Analysis for siRNAs
2:12
Routine Analysis for siRNAs
a day ago
by
Martina Lioi
Is SPE Transferable to Routine Pharma Labs?
1:08
Is SPE Transferable to Routine Pharma Labs?
a day ago
by
Tony Edge
Daniel Meston, Agilent Technologies
0:35
The Role of Perfusion Chromatography
2 days ago
by
Daniel Meston
Steven Ray Wilson, University of Oslo
0:55
The Evolution of Organoid Research
10 days ago
by
Steven Ray Wilson
Gérard Hopfgartner, University of Geneva
0:46
Making the ESI-APPI Workflow Practical for LC-MS
16 days ago
by
Gérard Hopfgartner
Jonathan Maurer, University of Geneva
1:04
Adapting Column Technology for mRNA
17 days ago
by
Jonathan Maurer
Jonathan Maurer, University of Geneva
0:51
Building the Analytical Toolbox for mRNA Characterization
22 days ago
by
Jonathan Maurer
Erin Chambers, Waters Corporation
1:04
The Best Leadership Advice to Live By
24 days ago
by
Erin E. Chambers
Erin Chambers, Waters Corporation
0:43
The Precision Needed for GLP-1 Testing
a month ago
by
Erin E. Chambers

Advancing Miniaturized Column and Instrument Technologies for Capillary Liquid Chromatography

A Look at Recent Updates

Advancing Miniaturized Column and Instrument Technologies for Capillary Liquid Chromatography

LCGC International July/August Issue

Read the Latest Cutting-Edge Articles from LCGC

LCGC International July/August Issue

Separation Science in 2025–2026: The Products Shaping Analytical Workflows

Read More About the Latest Cutting-Edge Technology on the Market

Separation Science in 2025–2026: The Products Shaping Analytical Workflows

Why are Most Drugs Basic: Implications in Pharmaceutical Testing by HPLC

Why Do Basic Drugs Dominate Modern Therapeutics?

Why are Most Drugs Basic: Implications in Pharmaceutical Testing by HPLC

The Column June Issue

A Look at the Latest Applications, Articles, and Interviews from the World of Chromatography

The Column June Issue

Podcasts



All Content

Comparing manual and automated N-glycan profiling of a trastuzumab biosimilar, researchers found that both workflows detected the same glycan types, but automation gave more reproducible results (mean CV of about 5.7% vs. 7.95%), making it better suited to high-throughput analysis in biopharmaceutical development.